# Insight Molecular Diagnostics to Report Q3 Results Nov. 16

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/57064
Published: 2026-11-13T22:47:41.000Z
Updated: 2026-11-13T22:47:41.000Z
Section: Business

> Consensus estimates put earnings per share at a loss of $0.22, with a reported 35.3% year-over-year increase. Revenue is projected at $240,000, down 7.7%.

Insight Molecular Diagnostics Inc. (IMDX) is scheduled to release third-quarter results after the market closes Monday, Nov. 16, with consensus estimates calling for a per-share loss and lower revenue.

The consensus earnings-per-share estimate is a loss of $0.22, with a 35.3% year-over-year increase. Revenue is forecast at $240,000, down 7.7% from a year earlier.

The company’s shares trade on Nasdaq.